

Abraham Avigdor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10211308/publications.pdf>

Version: 2024-02-01

76
papers

1,979
citations

411340

20
h-index

299063

42
g-index

76
all docs

76
docs citations

76
times ranked

3199
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 625-634.	1.7	83
2	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. <i>Journal of the National Cancer Institute</i> , 2022, 114, 436-445.	3.0	29
3	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. <i>British Journal of Haematology</i> , 2022, 196, 884-891.	1.2	48
4	ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy. <i>Annals of Hematology</i> , 2022, 101, 309-316.	0.8	4
5	Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol. <i>Annals of Hematology</i> , 2022, 101, 581-593.	0.8	4
6	Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072110661.	1.1	3
7	Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis. <i>Annals of Hematology</i> , 2022, 101, 755.	0.8	1
8	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 251-257.	0.6	14
9	Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies. <i>Cells</i> , 2022, 11, 1140.	1.8	8
10	Favezelimab (anti-“LAG-3) plus pembrolizumab in patients with anti-“PD-1-“naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7516-7516.	0.8	2
11	Favezelimab (anti-“LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-“PD-1 treatment: An open-label phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7545-7545.	0.8	7
12	Multiple Myeloma Presenting in Patients Younger than 50 Years of Age: A Single Institution Experience. <i>Acta Haematologica</i> , 2021, 144, 58-65.	0.7	8
13	Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 118-124.	0.6	23
14	A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia. <i>European Journal of Haematology</i> , 2021, 106, 260-266.	1.1	3
15	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. <i>Leukemia and Lymphoma</i> , 2021, 62, 1692-1701.	0.6	22
16	Phase 1 first-in-human study of ABBV-184 monotherapy in adult patients with previously treated acute myeloid leukemia or non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2674-TPS2674.	0.8	0
17	Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e929-e937.	0.2	4
18	Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies. <i>Nature Communications</i> , 2021, 12, 5581.	5.8	8

#	ARTICLE	IF	CITATIONS
19	Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	3
20	CAR T cells for the long run in aggressive B-cell lymphoma. <i>Lancet Oncology</i> , The, 2021, 22, 1347-1348.	5.1	0
21	Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients. <i>Blood</i> , 2021, 138, 910-910.	0.6	1
22	ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy. <i>Blood</i> , 2021, 138, 3392-3392.	0.6	0
23	Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy. <i>Blood</i> , 2021, 138, 3390-3390.	0.6	0
24	Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203). <i>Blood</i> , 2021, 138, 813-813.	0.6	7
25	PET/CT in Disease Detection and Follow-up of Subcutaneous Involvement in Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 252-259.	0.2	1
26	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. <i>Current Research in Translational Medicine</i> , 2020, 68, 17-22.	1.2	24
27	Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e947-e955.	0.2	4
28	Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome. <i>Leukemia and Lymphoma</i> , 2020, 61, 2645-2651.	0.6	3
29	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3188-3197.	0.6	26
30	LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1736-1743.	1.3	11
31	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. , 2020, 8, e000148.		42
32	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203). <i>Blood</i> , 2020, 136, 36-37.	0.6	6
33	Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 43-45.	0.6	41
34	Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia. <i>Oncotarget</i> , 2020, 11, 2233-2245.	0.8	4
35	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204). <i>Blood</i> , 2020, 136, 27-28.	0.6	9
36	Romidepsin treatment for relapsed or refractory peripheral and cutaneous Tâ€cell lymphoma: Realâ€life data from a national multicenter observational study. <i>Hematological Oncology</i> , 2019, 37, 569-577.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. <i>Pharmaceutical Research</i> , 2019, 36, 93.	1.7	4
38	Early and late hematologic toxicity following CD19 CAR-T cells. <i>Bone Marrow Transplantation</i> , 2019, 54, 1643-1650.	1.3	254
39	Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma. <i>Acta Haematologica</i> , 2019, 141, 84-90.	0.7	10
40	Is fluorescence <i>in-situ</i> hybridization sufficient in patients with myelodysplastic syndromes and insufficient cytogenetic testing?. <i>Leukemia and Lymphoma</i> , 2019, 60, 764-771.	0.6	3
41	Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT. <i>Abdominal Radiology</i> , 2018, 43, 2369-2374.	1.0	9
42	FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes. <i>Leukemia and Lymphoma</i> , 2018, 59, 348-356.	0.6	24
43	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-462.	0.8	169
44	Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1485-1492.	2.0	93
45	CAR T cells induce a complete response in refractory Burkitt Lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1583-1585.	1.3	25
46	STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models. <i>Oncotarget</i> , 2018, 9, 31367-31379.	0.8	4
47	Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma – Interim Analysis of Phase II Clinical Trial. <i>Blood</i> , 2018, 132, 4186-4186.	0.6	3
48	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.	0.6	209
49	Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 65, 1-7.	0.6	30
50	Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 710-718.	1.5	28
51	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology</i> , The, 2016, 17, 200-211.	5.1	373
52	Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. <i>Leukemia and Lymphoma</i> , 2016, 57, 63-69.	0.6	25
53	The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo. <i>Oncotarget</i> , 2016, 7, 62572-62584.	0.8	3
54	The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression. <i>Blood</i> , 2016, 128, 767-767.	0.6	0

#	ARTICLE	IF	CITATIONS
55	STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy. <i>Blood</i> , 2015, 126, 5348-5348.	0.6	0
56	Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucoseâ€“positron emission tomography/computed tomography in mantle cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2484-2489.	0.6	23
57	The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1297-1304.	0.8	53
58	Infections Associated with Bendamustine â€“ a Retrospective Multicenter Study. <i>Blood</i> , 2014, 124, 3077-3077.	0.6	0
59	High Risk Advanced Stage Hodgkin Lymphoma Is Well Controlled with 2 Cycles of Escalated Beacopp Followed By 4 Cycles of ABVD in Patients Who Rapidly Achieve Metabolic CR on Interim PET/CT Scan. <i>Blood</i> , 2014, 124, 4442-4442.	0.6	0
60	Staging DLBCL: bone marrow biopsy or PET-CT?. <i>Blood</i> , 2013, 122, 4-5.	0.6	16
61	Combination Of Fluorescence In Situ Hybridization (FISH) and Cytogenetic Techniques Optimize The Diagnostic Process Of Patients With Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2013, 122, 5210-5210.	0.6	0
62	Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses â€“ First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. <i>Blood</i> , 2012, 120, 550-550.	0.6	8
63	A Multi-Center Prospective Randomized Study Comparing Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) Vs. BEAM Alone as the Conditioning Regimen Prior to Autologous Stem-Cell Transplantation In Patients with Aggressive Lymphoma; Possible Advantage for Z-BEAM In Low-Risk Patients. <i>Blood</i> , 2010, 116, 686-686.	0.6	2
64	Combination of Rituximab with Initial Chemotherapy Improves Outcome of Primary Mediastinal B-Cell Lymphoma: A Retrospective Analysis of a Single Institution Cohort. <i>Blood</i> , 2007, 110, 1283-1283.	0.6	6
65	Combined escBEACOPP-ABVD Therapy for Advanced Hodgkinâ€™s Lymphoma Patients with High IPS Score: An Effective Regimen and Low Positive Predictive Value of Early FDG-PET/CT Scan.. <i>Blood</i> , 2007, 110, 2319-2319.	0.6	3
66	Prognostic Significance of VEGF, VEGF Receptors, and Microvessel Density in Diffuse Large B Cell Lymphoma Treated with Anthracycline-Based Chemotherapy.. <i>Blood</i> , 2007, 110, 53-53.	0.6	3
67	MT1-MMP and RECK Inversely Regulate Hematopoietic Progenitor Cell Egress.. <i>Blood</i> , 2007, 110, 1259-1259.	0.6	0
68	The Oncoprotein LMO2 Is Expressed in a Germinal Center B-Cell-Associated Pattern and Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 810-810.	0.6	0
69	Ibritumomab Tiuxetan (Zevalin) in the Conditioning Regimen for Autologous and Reduced-Intensity Allogeneic Stem-Cell Transplantation in Patients with Chemo-Refractory Non-Hodgkinâ€™s Lymphoma.. <i>Blood</i> , 2005, 106, 1131-1131.	0.6	2
70	Prolongation of Post Relapse and Overall Survival in Patients with Multiple Myeloma by Salvage Strategy with the Combination of Thalidomide and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation Based on the Nature of Disease Progression after Autologous Bone Marrow Transplantation.. <i>Blood</i> , 2005, 106, 3494-3494.	0.6	0
71	Membrane Type 1-Matrix Metalloproteinase Is Directly Involved in G-CSF Induced Human Hematopoietic Stem and Progenitor Cell Mobilization.. <i>Blood</i> , 2004, 104, 2675-2675.	0.6	7
72	CD45 Phosphatase Is Involved in Motility and Development of Hematopoietic Stem and Maturing Cells by the Regulation of Cell Adhesion and Cytokine Signaling.. <i>Blood</i> , 2004, 104, 119-119.	0.6	3

#	ARTICLE	IF	CITATIONS
73	A Pilot Study of Combined Escalated BEACOPP-ABVD Therapy for Advanced Hodgkin's Lymphoma Patients with High IPS Score: The Israel Cooperative Lymphoma Group.. Blood, 2004, 104, 4576-4576.	0.6	0
74	Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma. Leukemia and Lymphoma, 2001, 42, 683-687.	0.6	62
75	Diffuse Alveolar Hemorrhage in Acute Promyelocytic Leukemia Patients Treated with ATRA - A Manifestation of the Basic Disease or the Treatment. Leukemia and Lymphoma, 2000, 37, 605-610.	0.6	53
76	First-line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes. EJHaem, 0, , .	0.4	2